Identification of a nonsteroidal liver X receptor agonist through parallel array synthesis of tertiary amines.
about
Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissueThe three-dimensional structure of the liver X receptor beta reveals a flexible ligand-binding pocket that can accommodate fundamentally different ligandsLigand activation of LXR beta reverses atherosclerosis and cellular cholesterol overload in mice lacking LXR alpha and apoEOxysterol and diabetes activate STAT3 and control endothelial expression of profilin-1 via OSBP1Characterization of Adipogenic Chemicals in Three Different Cell Culture Systems: Implications for Reproducibility Based on Cell Source and HandlingDifferential regulation of gene expression by LXRs in response to macrophage cholesterol loadingStructural overview of the nuclear receptor superfamily: insights into physiology and therapeutics.Androgen deprivation by activating the liver X receptor.The Concise Guide to PHARMACOLOGY 2013/14: nuclear hormone receptors.RAP250 is a coactivator in the transforming growth factor beta signaling pathway that interacts with Smad2 and Smad3.The benzenesulfoamide T0901317 [N-(2,2,2-trifluoroethyl)-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-benzenesulfonamide] is a novel retinoic acid receptor-related orphan receptor-alpha/gamma inverse agonist.Liver X receptor ligands suppress ubiquitination and degradation of LXRalpha by displacing BARD1/BRCA1.Minireview: liver X receptor beta: emerging roles in physiology and diseases.The macrophage LBP gene is an LXR target that promotes macrophage survival and atherosclerosis.Activation of liver X receptor reduces global ischemic brain injury by reduction of nuclear factor-kappaBOrphan nuclear receptor DAX-1 acts as a novel corepressor of liver X receptor alpha and inhibits hepatic lipogenesis.LXR modulation blocks prostaglandin E2 production and matrix degradation in cartilage and alleviates pain in a rat osteoarthritis model.Regulation of type 1 iodothyronine deiodinase by LXRαRhythmic modulation of the hematopoietic niche through neutrophil clearance.Stimulation of the liver X receptor pathway inhibits HIV-1 replication via induction of ATP-binding cassette transporter A1Transcriptional regulation of human hydroxysteroid sulfotransferase SULT2A1 by LXRα.Nuclear receptor engineering based on novel structure activity relationships revealed by farnesyl pyrophosphate.Identification of novel liver X receptor activators by structure-based modelingInhibitory effect of LXR activation on cell proliferation and cell cycle progression through lipogenic activity.A functional cross-talk between liver X receptor-α and constitutive androstane receptor links lipogenesis and xenobiotic responses.LXR-mediated inhibition of CD4+ T helper cells.LIM-only protein FHL2 is a positive regulator of liver X receptors in smooth muscle cells involved in lipid homeostasisBoth liver-X receptor (LXR) isoforms control energy expenditure by regulating brown adipose tissue activity.The promise and peril of chemical probes.TTC39B deficiency stabilizes LXR reducing both atherosclerosis and steatohepatitis.Evolution of promiscuous nuclear hormone receptors: LXR, FXR, VDR, PXR, and CARActivation of the liver X receptor increases neuroactive steroid levels and protects from diabetes-induced peripheral neuropathy.The LXR-Idol axis differentially regulates plasma LDL levels in primates and miceLow dose of the liver X receptor agonist, AZ876, reduces atherosclerosis in APOE*3Leiden mice without affecting liver or plasma triglyceride levels.MicroRNA hsa-miR-613 targets the human LXRα gene and mediates a feedback loop of LXRα autoregulation.RIP140 contributes to foam cell formation and atherosclerosis by regulating cholesterol homeostasis in macrophages.Differential interactions of antiretroviral agents with LXR, ER and GR nuclear receptors: potential contributing factors to adverse eventsDifferential effects of 24-hydroxycholesterol and 27-hydroxycholesterol on tyrosine hydroxylase and alpha-synuclein in human neuroblastoma SH-SY5Y cells.The oxysterol 27-hydroxycholesterol regulates α-synuclein and tyrosine hydroxylase expression levels in human neuroblastoma cells through modulation of liver X receptors and estrogen receptors--relevance to Parkinson's disease.Targeted Delivery of LXR Agonist Using a Site-Specific Antibody-Drug Conjugate
P2860
Q24677042-0B76B94E-FD33-40C9-82CA-BB6916D7BD16Q27641458-42F22942-1521-4501-BC40-E35C804696FBQ28513193-98832111-ADC8-4913-9B34-E46C9C3793FEQ28571298-A1EB7261-C51C-475E-95D9-7FEAF8F3944DQ28817260-55EC16A1-57B0-4C83-82A4-78203B30D525Q30412216-64D023D4-F953-412D-B085-0AB4E1051AA9Q30418832-1DFA7753-0395-478F-A6DA-F2C6ECAAA91BQ30439040-1167D84F-0791-4D22-B41E-D959BA984272Q30486738-188B3579-C8C0-4C17-877B-7C85247E1B2FQ33319067-3549C274-3C68-4534-82B2-146E6C3B4F0FQ33613397-B28D2BD3-39FC-4725-A54D-AA00A2C2AE6EQ33642453-C2DDCA12-3252-433D-8C17-4C4A18AC5663Q33642516-1D21383D-2E6B-49F5-8031-5FBB71635C3EQ33653635-DE19EFB7-D86C-40FC-9C02-CD9A3D1A13F5Q33708001-2AB8806B-C967-4F19-A15F-A95CA8BC7296Q33726647-9BC27019-82AC-4482-A3CF-C964D383B18DQ33734592-BDB8A4C2-42DD-45ED-983E-D21EB4105AFBQ33803303-56A9EDE2-CEFF-498E-A350-B725D85EA0B8Q34026142-B9847932-41C7-4DF8-A2E7-DE7DA5520590Q34051644-97EE53DA-27A0-4870-8118-F1B89490A1FDQ34185996-32261E97-9224-4EF1-8222-CAB9F2FD1BC5Q34193867-26176C81-6671-44F3-8DD0-04DAEBAB74C9Q34226831-14FA1AB1-B010-4E29-8F61-309B2A7F0DFAQ34287799-206AD133-1D44-42CA-8F64-C14F45B52A52Q34310040-8D2C3441-47B2-40F4-AED0-18B1C840A865Q34431434-FDA3FD59-5CB2-43E3-9EA0-13D18BC65367Q34444310-F8A510BB-0CF5-403B-9679-B5336F264FAAQ34471849-831A6A9E-0194-4943-A7AE-F697CBEE639AQ34486195-79D4731B-5516-4252-8105-482F6C9574C8Q34533119-301936AE-29C0-4E94-BD5E-B9FB600A3BCDQ34550999-E20F1E1D-2D22-4990-BE50-6863271EB327Q34626341-93F7FAD7-8BA0-4DC2-8CD6-9569C2AB081BQ34667908-6DA4E118-23A8-45E0-827C-6034159A979BQ34672078-1CC37B14-A185-4EE9-B473-16C68D08C08AQ34712126-992A8736-63CA-41BB-9B4D-8ADD98F6EA8DQ34995879-4602F2A2-1C2C-4C1B-B18A-700014D608C0Q35076628-DD2E7608-41EF-438D-96C7-A4452D801608Q35492403-A2795225-C0F9-4422-BCB4-7927D5330442Q35552497-FE534355-E12C-4A78-B9C9-99B02116ED93Q36296686-D6782176-77FF-45EB-BD2E-D710F368D2C0
P2860
Identification of a nonsteroidal liver X receptor agonist through parallel array synthesis of tertiary amines.
description
2002 nî lūn-bûn
@nan
2002 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Identification of a nonsteroid ...... synthesis of tertiary amines.
@ast
Identification of a nonsteroid ...... synthesis of tertiary amines.
@en
type
label
Identification of a nonsteroid ...... synthesis of tertiary amines.
@ast
Identification of a nonsteroid ...... synthesis of tertiary amines.
@en
prefLabel
Identification of a nonsteroid ...... synthesis of tertiary amines.
@ast
Identification of a nonsteroid ...... synthesis of tertiary amines.
@en
P2093
P356
P1476
Identification of a nonsteroid ...... synthesis of tertiary amines.
@en
P2093
Adam M Fivush
Cristin M Galardi
Daniel G Morgan
Derek J Parks
Elizabeth J Beaudet
Jane G Binz
Joan G Wilson
Jon L Collins
Karl D Whitney
Kelli D Plunket
P304
P356
10.1021/JM0255116
P407
P577
2002-05-01T00:00:00Z